Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
DualityBio receives $45m upfront payment in billion-dollar ADC partnership with Genentech
DualityBio and Genentech have entered a collaboration and license agreement to develop antibody–drug conjugates (ADCs) based on the DUPAC payload platform. DualityBio will receive a $45 million upfront payment plus potential milestone payments of more than $1 billion and tiered royalties. DualityBio will lead research and early clinical development; Genentech receives exclusive worldwide licenses and will take over further development and commercialization after phase 1a. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 14.14m | 80.56% |
| Gross profit | -15.05m | 143.12% |
| Net profit | -59.17m | 51.82% |
| EBITDA | -62.11m | 955.82% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.73bn |
Number of shares | 90.48m |
52-week high/low | €61.16 - €17.50 |
| Dividends | No |
Beta | 1.40 |
P/E ratio | -9.19 |
PEG ratio | -0.08 |
P/B ratio | 9.16 |
P/S ratio | 15.88 |
Company profile
Duality Biotherapeutics, Inc. ist ein Unternehmen in der klinischen Phase. Es konzentriert sich auf die Entwicklung von Antikörper-Wirkstoff-Konjugat-Therapeutika der nächsten Generation und Duality-Immun-Toxin-Antikörper-Konjugat-Therapeutika. Das Unternehmen wurde am 3. Juli 2019 von Zhu Zhong Yuan gegründet und hat seinen Hauptsitz in Shanghai, China.
| Name | Duality Biotherapeutics Inc |
| CEO | Zhongyuan Zhu |
| Website | |
| IPO | 15/04/2025 |
| Employees | 231 |
